Skip to main content
Erschienen in: Diabetologia 9/2009

01.09.2009 | Short Communication

Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes

verfasst von: P. Wiesli, P. Krayenbühl, H. Uthoff, B. Seifert, C. Schmid

Erschienen in: Diabetologia | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The aim of this prospective trial was to compare the effect of different long-acting insulin preparations injected at bedtime on glucose concentrations in patients with type 2 diabetes omitting breakfast and lunch the next day.

Methods

Twenty patients (ten women) with type 2 diabetes who were on an intensified insulin therapy participated. Mean (±SD) age was 63 ± 10 years, diabetes duration 18 ± 9 years, BMI 32.5 ± 5 kg/m2, and HbA1c 7.3 ± 0.7%. Patients received neutral protamine Hagedorn (NPH) insulin, insulin detemir or insulin glargine for at least 2 months; doses were adjusted to achieve morning blood glucose levels of <7 mmol/l. At the end of the respective treatment period, the long-acting insulin was injected at bedtime (at 22:45 hours) as usual but patients refrained from breakfast and lunch the next day; glucose was measured by a continuous glucose monitoring system (CGMS).

Results

Comparable glucose target ranges were reached at midnight (5.8 to 6.1 mmol/l) and at 07:00 hours (6.7 to 6.9 mmol/l) with all three insulin preparations, using mean doses of 29 ± 10 U (NPH insulin), 33 ± 13 U (insulin detemir), and 32 ± 12 U (insulin glargine). Glucose levels between midnight and 07:00 hours were not significantly different for the three insulin preparations. Symptomatic hypoglycaemia did not occur from 08:00 to 16:00 hours; glucose concentrations during this time were slightly lower with NPH insulin than with insulin detemir (p = 0.012) and insulin glargine (p = 0.049).

Conclusions/interpretation

Following bedtime injection of NPH insulin or of the analogues insulin detemir or insulin glargine, fasting glucose <7 mmol/l was achieved in the morning, without subsequent hypoglycaemia when participants continued to fast during the day.
Literatur
1.
Zurück zum Zitat Heise T, Nosek L, Rønn B et al (2004) Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614–1620PubMedCrossRef Heise T, Nosek L, Rønn B et al (2004) Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614–1620PubMedCrossRef
2.
Zurück zum Zitat Plank J, Bodenlenz M, Sinner F et al (2005) A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28:1107–1112PubMedCrossRef Plank J, Bodenlenz M, Sinner F et al (2005) A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28:1107–1112PubMedCrossRef
3.
Zurück zum Zitat Lepore M, Pampanelli S, Fanelli C et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148CrossRef Lepore M, Pampanelli S, Fanelli C et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148CrossRef
4.
Zurück zum Zitat Swinnen S, Holleman F, DeVries J (2008) The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 51:1790–1795PubMedCrossRef Swinnen S, Holleman F, DeVries J (2008) The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 51:1790–1795PubMedCrossRef
5.
Zurück zum Zitat Holleman F, Gale E (2007) Nice insulins, pity about the evidence. Diabetologia 50:1783–1790PubMedCrossRef Holleman F, Gale E (2007) Nice insulins, pity about the evidence. Diabetologia 50:1783–1790PubMedCrossRef
6.
Zurück zum Zitat Trümper B, Reschke K, Molling J (1995) Circadian variation of insulin requirement in insulin dependent diabetes mellitus the relationship between circadian change in insulin demand and diurnal patterns of growth hormone, cortisol and glucagon during euglycemia. Horm Metab Res 27:141–147PubMedCrossRef Trümper B, Reschke K, Molling J (1995) Circadian variation of insulin requirement in insulin dependent diabetes mellitus the relationship between circadian change in insulin demand and diurnal patterns of growth hormone, cortisol and glucagon during euglycemia. Horm Metab Res 27:141–147PubMedCrossRef
7.
Zurück zum Zitat Shapiro E, Polonsky K, Copinschi G et al (1991) Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes. J Clin Endocrinol Metab 72:444–454PubMedCrossRef Shapiro E, Polonsky K, Copinschi G et al (1991) Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes. J Clin Endocrinol Metab 72:444–454PubMedCrossRef
8.
Zurück zum Zitat Wiesli P, Lehmann R, Krayenbuehl P, Schmid C, Spinas G (2006) Assessment of basal insulin requirement using fasting tests in insulin-treated patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 114:539–543PubMedCrossRef Wiesli P, Lehmann R, Krayenbuehl P, Schmid C, Spinas G (2006) Assessment of basal insulin requirement using fasting tests in insulin-treated patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 114:539–543PubMedCrossRef
9.
Zurück zum Zitat Cockcroft D, Gault M (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft D, Gault M (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
10.
Zurück zum Zitat Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000) Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649PubMedCrossRef Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000) Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649PubMedCrossRef
Metadaten
Titel
Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes
verfasst von
P. Wiesli
P. Krayenbühl
H. Uthoff
B. Seifert
C. Schmid
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 9/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1439-z

Weitere Artikel der Ausgabe 9/2009

Diabetologia 9/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.